Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Treace Medical Concepts (TMCI) Accumulated Depreciation & Amortization (2020 - 2025)

Treace Medical Concepts' Accumulated Depreciation & Amortization history spans 6 years, with the latest figure at $23.9 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 55.96% year-over-year to $23.9 million; the TTM value through Dec 2025 reached $23.9 million, up 55.96%, while the annual FY2025 figure was $23.9 million, 55.96% up from the prior year.
  • Accumulated Depreciation & Amortization reached $23.9 million in Q4 2025 per TMCI's latest filing, up from $21.8 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $23.9 million in Q4 2025 to a low of $117000.0 in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $9.2 million, with a median of $6.6 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: plummeted 61.51% in 2021, then surged 2418.8% in 2022.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $2.7 million in 2021, then skyrocketed by 55.64% to $4.3 million in 2022, then soared by 105.21% to $8.7 million in 2023, then skyrocketed by 74.95% to $15.3 million in 2024, then soared by 55.96% to $23.9 million in 2025.
  • Per Business Quant, the three most recent readings for TMCI's Accumulated Depreciation & Amortization are $23.9 million (Q4 2025), $21.8 million (Q3 2025), and $19.6 million (Q2 2025).